Today's Healthcare Pulse
FDA greenlights durvalumab combo for high‑risk bladder cancer
The FDA approved durvalumab (Imfinzi) combined with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The POTOMAC trial enrolled 1,018 patients and showed a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015). Durvalumab is given at 1,500 mg IV every four weeks for up to 13 cycles.
Also developing:
By the numbers: Apogee Therapeutics raises $1.3B royalty financing
Mark Cuban’s Cost Plus Drugs And Humana In Deal To Take On Employer Drug Costs
Mark Cuban’s Cost Plus Drug Company has partnered with Humana’s CenterWell Pharmacy to create end‑to‑end employer prescription solutions. The deal leverages Cost Plus’s low‑price model and its SwiftyRx digital platform alongside CenterWell’s distribution network and more than 500 pharmacists. While financial terms were not disclosed, the collaboration aims to simplify drug access, reduce fill costs and offer home delivery for Humana’s workforce of over 67,000 employees. The initiative arrives as U.S. employer health‑care spending is projected to exceed $17,000 per employee, a 9% year‑over‑year rise.
Care Home Manager Struck Off over 'Horrific' Restraining of Disabled Person
A tribunal in Ayrshire stripped care home manager Janette Donnelly of her nursing licence after she forcibly restrained a disabled resident to administer a COVID‑19 vaccine through the resident’s clothing. The panel described the restraint as "horrific" and found Donnelly...
RFK Jr. Vows to End ‘Illusion’ of Lower Premiums Under ACA
U.S. Health and Human Services Secretary Robert F. Kennedy Jr. testified before the House Ways & Means and Education & Workforce committees, arguing that the Affordable Care Act’s subsidy structure creates an illusion of lower premiums while actually benefiting insurers....
Lawmakers Introduce Bipartisan Bill to Speed up Prior Authorization in Medicare Advantage
Congress introduced the bipartisan Medicare Advantage Improvement Act to cut prior‑authorization delays. The bill mandates health plans to complete standard authorizations within 72 hours and publish timing data. It also requires real‑time, EHR‑integrated approval systems and limits extensions to seven...
Unverified Tips Can Mislead: False Compass Data
Interesting side note on today's disappointing $CMPX results: Yesterday, I received a message on Signal from someone claiming to be a Compass employee. He gave me the purported tovecimig PFS and OS data. I didn't do anything with the supposedly material...
Radiologists Among Docs Most Optimistic About Profession’s Short-Term Future
Radiologists lead physician specialists in short‑term optimism, with 69% viewing the next three years positively, according to Medscape’s 2024 survey of 177 radiologists. That confidence evaporates for the long term, where only 42% remain optimistic—a 27‑point drop that places radiology...
India Busts Massive Counterfeit Food and Drug Operation
🚨 INDIA EATING POISON 🚨 Delhi - Fake toothpaste factory: 1,800 filled tubes, 10,000 empty tubes, 1,200 packed units and 130kg of raw material of Sensodyne toothpaste. - Fake Eno sachets: 1 lakh. - Fake Nescafé sachets: 50,000. Ayodhya - 500 cartons of fake Fortune oil...
Motif Neurotech Receives FDA IDE Approval to Initiate RESONATE Trial of Motif XCS System in Treatment-Resistant Depression
Motif Neurotech has secured FDA Investigational Device Exemption (IDE) to launch the RESONATE early feasibility study of its Motif XCS System in patients with treatment‑resistant depression who have failed at least two medications. The trial will monitor 12‑month safety, symptom...
Rapamycin and Psoriasis
Rapamycin, an mTOR inhibitor used for longevity, is being discussed as a possible psoriasis treatment. The forum post highlights oral versus topical administration, noting early positive skin‑aging results for topical use but no definitive clinical evidence for psoriasis clearance. Users...
Kingstec Advances Real-Time Medical Asset Tracking
Kingstec Technologies announced the rollout of Technology Trace Inc.’s trevii real‑time medical asset tracking platform at St. Joseph’s Healthcare Hamilton. A year‑long pilot delivered a 100% reconciliation rate and 98% floor‑level location accuracy, demonstrating the system’s reliability. Kingstec acted as the...
Bariatric Surgery Vs. Semaglutides Vs. Endoscopic Visceral Lipectomy
The article contrasts traditional bariatric surgery, GLP‑1 drug semaglutide, and the nascent endoscopic visceral lipectomy (EVL) as obesity interventions. It highlights semaglutide’s high cost, injection regimen, and 35‑50% one‑year discontinuation rate, while noting bariatric surgery’s nutritional risks and weight‑loss plateaus....
Cell, Gene And Specialty Drug Costs Intensify For Health Plans
A new Pharmaceutical Strategies Group survey of 228 benefits executives shows 43% of health plans rank controlling specialty drug costs as their top priority, ahead of total cost of care. Specialty medicines now consume more than half of prescription spending,...
STAT+: Veradermics’ Hair Loss Drug Succeeds in Late-Stage Trial
Veradermics announced that its oral hair loss drug VDPHL01 met primary endpoints in a Phase III trial. Over six months, participants taking the pill grew 30‑33 hairs per square centimeter versus seven in the placebo group. Patient‑reported improvement reached 79‑86%, and...
Zepbound’s and Ozempic’s Greatest Benefit May Be Their Anti-Inflammatory Power
GLP‑1 drugs such as Ozempic and Zepbound are gaining recognition for anti‑inflammatory effects that go beyond weight loss and glucose control. Clinical data show semaglutide reduces C‑reactive protein by about 40% independent of weight loss and improves liver inflammation in...
Study Links Vitamin E and Riboflavin to Hormone Levels and Muscle Mass in Infertile Women
Researchers published a cross‑sectional study of 97 women seeking infertility treatment in Spain, finding that higher vitamin E intake correlates with elevated anti‑Müllerian hormone (AMH) and that riboflavin consumption is positively associated with muscle‑mass percentage. The findings highlight nutrition as a...
CNN Profile Spotlights 14‑year‑old Mason as Autism Diagnoses Climb to 1 in 31 U.S. Children
CNN's new profile follows 14‑year‑old Mason of Texas, illustrating the lived reality of autism as CDC data shows the prevalence has risen to 1 in 31 children. The story combines expert commentary and a mother’s perspective to illuminate what parents...
Most Rotator Cuff “Tears” Aren’t True Tears
Are Most Rotator Cuff Tears Actually Tears? This topic is far, far more complicated than most think... and it's certainly far more complicated than the discussion in most office visits portrays. 1/ If you have a rotator cuff tear on an...
Physicians Unwittingly Donate Year‑Long Unpaid Labor
A pediatrician added up the hours she had donated to her medical school as a volunteer clinical professor. Over 2,000. That is more than a full year of full-time work. Donated. While running clinic, holding leadership roles, and raising three...
Ascletis Completes Enrollment in U.S. Phase‑II Trial of Oral GLP‑1 Agonist ASC30
Ascletis Pharma announced that its 13‑week U.S. Phase‑II trial of ASC30, an oral small‑molecule GLP‑1 receptor agonist for type‑2 diabetes, has enrolled 100 participants. The company expects topline results in the third quarter of 2026, a milestone that could reshape...
Vaccination and Boosters Are Key to Preventing Long COVID
The best way to prevent long Covid is through vaccination and annual updates or boosters https://t.co/m56zh2o2ZY
Chromosomal Abnormalities Impact Myeloma Survival Differently Across Populations
Population differences in the associations between chromosomal abnormalities and overall survival of multiple myeloma [Jan 31, 2025] Bei Wang et al. @Bloodneoplasia https://t.co/IFPgCwpGo6 #mmsm #PrecisionMedicine #cancerdisparities https://t.co/vpNoEupRPG
NICE Launches Consultation on New Topic Prioritisation Framework
NICE has opened a consultation to overhaul its topic prioritisation manual, aligning it more closely with NHS priorities and national policy. The proposed changes introduce clearer priority definitions, merge the two‑stage framework into a single streamlined process, and adopt a...
High CTC Levels Signal Aggressive, Genomically Complex Myeloma
Elevated circulating tumor cells [#cactc] reflect high proliferation and genomic complexity in multiple myeloma [Sep 23, 2025] Garces et al. @Hemasphere_EHA https://t.co/R8ehW89gTn #mmsm #cagenome https://t.co/Ms6SGwbxcL
Fathom Therapeutics Secures $47M Series A for AI‑Physics Drug Discovery
Exclusive: Fathom Therapeutics, formerly Atommap, has raised a $47M Series A, building a pipeline with its strategy of blending AI and physics approaches to drug discovery: https://t.co/iAlmJwCQK7
AstraZeneca Reports FDA Approval of Saphnelo for Systemic Lupus Erythematosus (SLE)
The U.S. Food and Drug Administration has granted approval for AstraZeneca’s Saphnelo autoinjector (anifrolumab, 120 mg weekly) for adult patients with systemic lupus erythematosus (SLE) when used alongside standard of care. The decision follows the Phase III TULIP‑SC trial, which enrolled 367...
CRISPR Therapy Cuts Swelling Attacks 87%, 60% Attack‑Free
$NTLA Intellia says CRISPR-based treatment for rare disease reduced swelling attacks in pivotal trial Attack rates dropped 87%, relative to placebo. Just over 60% were entirely attack-free over the period, compared to 11% for the placebo patients. https://t.co/ljPC7Lww0D via @Jasonmmast
Oruka's Long-Acting Psoriasis Drug Achieves 63% PASI‑100
$ORKA Oruka’s long-acting psoriasis therapy posts strong results in mid-stage study 63% PASI 100 score at 16 weeks, very strong data. https://t.co/RJxnbuU0e3 via me
Novartis Secures Pair of Regulatory Wins for Skin Disease and Malaria Treatments
Novartis won two regulatory milestones: the European Commission approved its oral BTK inhibitor Rhapsido for adults with chronic spontaneous urticaria who have failed antihistamines, and the World Health Organization granted prequalification to Coartem Baby, an artemether‑lumefantrine formulation for infants weighing 2‑5 kg....
New Book Chronicles Sickle Cell's History and Cure Quest
📢My new book is out on Sept 8th from @Harvard_Press: 'Curved Air: A Biography of Sickle Cell Anemia and the Quest to Cure the First Molecular Disease.' Some early testimonials.... @EricTopol @PeterHotez https://t.co/o3DKXW7d8t #sicklecelldisease https://t.co/4yrsbdDFe0
Veradermics' Hair Loss Drug Clears Late-Stage Trial
Ok, here we go... $MANE Veradermics' hair loss drug succeeds in late-stage trial. A report from @ADeAngelis_bio https://t.co/jtSB36sPGO
U.S. Hospitals Roll Out AI Chatbots as Doctors Split on Safety and Speed
Hospitals across the United States have launched AI‑driven chatbots—Patient GPT at Hartford HealthCare and Emmie at Sutter Health and Reid Health—to streamline appointments and answer clinical questions. While the tools promise faster access for patients, physicians remain wary of over‑reliance on...
Texas Researchers Claim Breakthrough for Younger, Stronger Brain
Want a Stronger, Younger Brain? Texas Researchers Say They Have Made a Fascinating Breakthrough https://t.co/FlYc78CxM7 #brainhealth #research
Leiden’s Sensor-Free Microrobots Move Like Living Organisms
Researchers at Leiden University have created soft, chain‑like microrobots that move and adapt without sensors, software, or external control. Each 5 µm segment is linked by 0.5 µm joints and powered solely by an electric field, allowing the robot’s shape to dictate...
Key Insights Await From Tovecimig Companion-002 Data
$CMPX data from Companion-002 study of tovecimig coming before 8am ET today. What to look out for, via @ByMadeleineA -> https://t.co/6IDCqMyNPE
Heart‑Metabolic Risks Accelerate Cognitive Decline in Indian Seniors
Cardiometabolic-Inflammatory Risk Factors and Cognitive Decline Among Older Indians—Report From a Nationally Representative, Longitudinal Study 'Longitudinal data provided by LASI-DAD study shed light on how cardiometabolic risk factors may influence decline of cognitive function and development of dementia in older adults...
Corporate Giants Eye $50 B Rural Health Fund as Medicaid Cuts Loom
The $50 billion Rural Health Transformation Program, created by the One Big Beautiful Bill Act, is drawing interest from large health‑tech coalitions eager to secure future payments. Small providers fear the influx of corporate money will dilute funds meant to offset...
New NIHR-Funded TRC for Parkinson’s Disease
The National Institute for Health and Care Research (NIHR) has launched the Parkinson’s disease Translational Research Collaboration (PD‑TRC), the first of eight UK TRCs dedicated to Parkinson’s. Backed by NIHR and four major charities, the hub links 17 centres of...
Lilly Falls on Slower Start for Foundayo versus Wegovy
Eli Lilly’s oral GLP‑1 agonist Foundayo launched in early April with modest uptake, recording 1,390 prescriptions in week 1 and 3,707 in week 2, far below Novo Nordisk’s oral Wegovy, which logged over 3,000 fills in its first days and 18,410 in the second...
Sun Pharma to Acquire Organon for $11.75 B, Boosting Women’s Health and Biosimilars
Sun Pharmaceutical Industries announced an all‑cash deal to acquire Organon & Co. for $14 per share, valuing the U.S. firm at $11.75 billion. The merger will lift Sun Pharma into the top‑25 global drugmakers, give it a top‑3 position in women’s...
How Can Pharma Prices Be Reduced for Americans Without Impacting Innovation?
President Trump announced a sweeping plan to impose 100% tariffs on branded pharmaceuticals, while offering exemptions to companies that sign most‑favored‑nation (MFN) agreements. The policy is framed as a way to force lower drug prices for American patients and to...
Miniature Pacemaker Revolutionizes Cardiac Care
Tiny Pacemaker, Big Impact: A Breakthrough in Cardiac Care by @pascal_bornet #HealthTech #Innovation #EmergingTech #TechForGood #Tech #Technology https://t.co/D8qNgYkx5i
The Deep State’s Medical Playbook
The episode critiques the Trump administration’s nomination of Navy doctor Erica Schwartz as CDC director, arguing she aligns with pro‑vaccine, “COVIDian” policies that threaten medical freedom. Guest Dr. Peter McCullough discusses alleged CIA suppression of Soviet research showing anti‑parasitic drugs like...
The WHO Is Building a Supranational Vaccine Authorization Mechanism
The World Health Organization’s Emergency Use Listing (EUL) has evolved from a temporary pandemic tool into a supranational framework that can shape national vaccine approvals. Israel’s Ministry of Health used the EUL to fast‑track the nOPV2 polio vaccine, effectively allowing...
As Coordination Grows More Complex, Intelligent Care Is Reshaping the Response
Intelligent care is emerging as a strategic framework that synchronizes people, processes, and technology across health systems. As patient flow becomes increasingly complex, many organizations still lack a unified, real‑time view of capacity, with only 17% reporting enterprise‑wide data visibility....
Florida Delays Children’s Health Insurance Expansion as Uninsured Rate Rises
Florida lawmakers approved a KidCare expansion in 2023 that would extend coverage to more than 40,000 additional children by raising the income threshold to 300% of the federal poverty level. Despite federal approval, the DeSantis administration has not implemented the...
Epic Controls 42% of the US EHR Market. Does that Help or Hurt Interoperability?
Epic controls 42.3% of the 2024 acute‑care EHR market, covering roughly 55% of U.S. hospital beds. The vendor’s open‑API strategy now supports over 2,500 third‑party apps and processes 252 billion transactions annually, while its Care Everywhere network moves 27 million charts each...
The Help That Many Older Americans Need Most
Community health workers (CHWs) are increasingly deployed in rural Oregon and Washington to address non‑medical needs of frail older adults, from transportation to housing assistance. A 90‑day pilot program, Connected Care for Older Adults, costs $1,500 per patient and has...
Why Health Plans Are Missing One of Their Most Costly Care Categories
Preference‑sensitive surgeries such as spine fusions, cataract procedures and hip replacements now represent roughly 30% of health‑plan medical spend and are growing 4‑6% annually. Up to 30% of these operations are medically inappropriate, costing commercial plans about $39 million and Medicare...
BrioHealth Secures FDA Approval to Launch BrioVAD System Trial
BrioHealth Solutions received conditional FDA approval to launch the Brio4Kids trial, testing its BrioVAD left ventricular assist device in children with advanced heart failure. Enrollment in the U.S. study is slated for mid‑2026, with initial data expected in the fourth...
Kyowa Kirin and Kura Initiate Phase II Trial of Ziftomenib for AML
Kyowa Kirin and Kura Oncology have opened a Japanese Phase II registrational study of the oral menin inhibitor ziftomenib in adults with relapsed or refractory NPM1‑mutated acute myeloid leukaemia. The single‑arm, open‑label trial will measure a composite complete remission rate (CR + CRh) as...